Hepatitis C Drug Market

Hepatitis C Drug Market Size

[170+ Pages Research Report] to surpass USD 8.87 billion by 2032 from USD 6.73 billion in 2021 at a CAGR of 2.5% throughout the forecast period 2022-32

Hepatitis C is a viral infection that leads to damage of the liver like severe inflammation and spreads through contaminated blood. Hepatitis C advanced stages lead to damage of liver, leading to major health risks. The Research and Development of drugs related to treatment of this disease increased due to the severity caused by hepatitis C. Due to the wide spread presence of hepatitis C, many new drugs are being identified and launched into the market. This disease requires oral injections dosage every weekly, and it leads to many side effects that might cause a permanent damage. Rise in clinical trials success has aided the hepatitis C market growth due to better drug clearances. Even the increase in regulatory approvals number will grow the hepatitis C market in the future.

Market Highlights

Hepatitis C drug Market is expected to project a CAGR of 2.5% during the forecast period.

The global hepatitis C drug market size was valued at 6.73 billion USD in 2021 and is projected to attain at 8.87 billion USD by 2032, exhibiting a CAGR of 2.5% during the forecast period. Hepatitis C market is at present at a unique position where the entry of new products into the market like the fixed-dose combination products which resulted in increased revenues generation by competing companies. The high prices of hepatitis C medicals is assigned due to the high costs along with the Research & Development procedures and the costs to bring drugs into the market.

Figure - Market Analysis of Hepatitis C Drug Market

Get More Information - Download Free Sample

Hepatitis C Drug Market: Segments

Fixed-dose Combination segment is expected to grow with a higher CAGR during 2022-32

Hepatitis C drug market globally is classified based on the product into Fixed-dose Combination, NS5A Inhibitor (Protease Inhibitors) and Others. The Fixed-dose Combination segment is expected to have a major share of the Hepatitis C therapeutics market due to the extreme therapy which is efficient for the treatment of Hepatitis. This segment is estimated to grow at a highest CAGR due to the features which are favourable like effectiveness in all the genotypes & due to the product launches held recently. There are several major drugs present in this segment, which result in acquiring new drug therapies.

Chronic Hepatitis C segment is expected to grow with a higher CAGR during 2022-32

Hepatitis C drug market is classified based on the disease type into acute Hepatitis C and Chronic Hepatitis C. In the disease type, the chronic Hepatitis C segment is expected to rise at a faster pace. This is due to all the acute Hepatitis C conditions converts into chronic form. Chronic Hepatitis C causes a long-term illness which needed a prolonged treatment or even for life time which is a factor contributing to the increase in the Hepatitis C drug market.

Figure - Market Analysis of Hepatitis C Drug Market

Get More Information - Download Free Sample

Market Dynamics                                                                                    

Growth Drivers

Invention of New Efficient Drugs

Globally, patient pool suffering from hepatitis C is large. There is a variation in trend being observed in patients due to increased effectiveness of drugs in treatment of Hepatitis C. The drugs used in the hepatitis C treatment are efficient and are superior resulting in reduced patient population indicating their superior extended activity. Novel advancements in technology to help in reducing the treatment cost will rise the demand for Hepatitis C drug market due to increase in Research & Development

Rise in Awareness and Support by Government

One of the forms of the hepatitis C, called the acute hepatitis C which will aid in the technical advancements and development of new treatment drugs. Certain initiatives by the government are made to improve the healthcare sector, to reduce the occurrence of Hepatitis C and the increased awareness about the disease burden is also a factor aiding the market growth.

Restraint

High Production Cost

The raw materials required for the manufacture of Hepatitis C drugs are high which might result in high production cost, high cost of finished product and in turn the investment required is high. Every step involved in the production like utilisation of raw materials and isolation involve a complex procedure which increases the overall cost of pharmaceuticals. Even the acute Hepatitis C at an early stage may not require the prescribing of therapeutic drugs. This is expected to restrain the market share of Hepatitis C drugs.

Recent Developments

• Mavyret, a newly launched medication by AbbVie, resulted in downfall of the Gilead revenue.
• In April 2019, U.S. FDA announced the approval the first-ever approved treatment for pediatric patients of all genotypes of hepatitis C, Mavyret by AbbVie.

Hepatitis C Drug Market: Key Players

• AbbVie Inc.

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

• Gilead Sciences, Inc.
• Janssen Pharmaceuticals, Inc.
• Kenilworth
• Bristol-Myers Squibb Company
• Merck Sharp & Dohme Corp.
• Zydus Cadillus
• LAURUS Labs
• F. Hoffmann-La Roche Ltd
• Hetero Healthcare Limited
• Cipla Inc.
• Basel GlaxoSmithKline
• Vertex Pharmaceuticals
• Other Prominent Players

Hepatitis C Drug Market: Regions

Hepatitis C Drug market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America is dominating the Hepatitis C drug market and is expected to rise in the market even during forecast period. Due the existence of large patient pool in these countries and concentration of patients suffering from hepatitis C in the area, result in high market growth of Hepatitis C drug. The prescribing of hepatitis C therapeutics is at a higher rate among healthcare providers and several patients are getting treated utilising these drugs. So, the launch of new medicines along with the strong Research and Development is helping the hepatitis C drug market to grow.

Get More Information - Download Free Sample

Impact of Covid-19 on Hepatitis C Drug Market

The lockdowns imposed by several countries to prevent the spread of Covid-19 resulted in the global operations and supply chain delay causing negative consequences on the Hepatitis C Drug market.  The global sales declined as the professionals involved in this healthcare diverted their attention on to coronavirus-infected patients. The key players in the market have suspended the production of Hepatitis C drugs temporarily for treating the patients affected with the Covid 19.

Hepatitis C Drug Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada

• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Global Hepatitis C Drug Market report also contains analysis on:

Global Hepatitis C Drug Market Segments:

• By Product 

  • NS5A Inhibitor (Protease Inhibitors)
  • Fixed-dose Combination
  • Others
• By Disease Type 
  • Acute Hepatitis C
  • Chronic Hepatitis C
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others 
• Hepatitis C Drug Market Dynamics
• Hepatitis C Drug Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies Involved in the Market
• Value Chain of the Market
• Market Drivers and Restraints

Hepatitis C Drug Market Report Scope and Segmentation

Frequently Asked Questions (FAQ):